US keeps India on IPR watch list but expectations run high
This article was originally published in Scrip
India stays a "priority watch list" partner nation that presents the most significant intellectual property rights (IPR)-related concerns for the US but was spared another immediate out-of-cycle review (OCR) in view of steps initiated by the Indian government indicating that it is "engaged and examining" key IPR issues.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.